These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 24400911)

  • 41. Identification of super enhancer-associated key genes for prognosis of germinal center B-cell type diffuse large B-cell lymphoma by integrated analysis.
    Li X; Duan Y; Hao Y
    BMC Med Genomics; 2021 Mar; 14(1):69. PubMed ID: 33663517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.
    Masir N; Akhter A; Roshan TM; Florence CS; Abdul-Rahman F; Tumian NR; Kean-Chang P; Elyamany G; Shabani-Rad MT; Mansoor A
    J Clin Pathol; 2019 Sep; 72(9):630-635. PubMed ID: 31189540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
    Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
    Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNA profiling of primary cutaneous large B-cell lymphomas.
    Koens L; Qin Y; Leung WY; Corver WE; Jansen PM; Willemze R; Vermeer MH; Tensen CP
    PLoS One; 2013; 8(12):e82471. PubMed ID: 24358187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.
    Hu M; Wang X; Liu N; Ding K; Zhang G; Liu X
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34109978
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression.
    Deng W; Clipson A; Liu H; Huang Y; Dobson R; Wang M; Johnson P; Du MQ
    Transl Oncol; 2018 Oct; 11(5):1147-1154. PubMed ID: 30055346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma.
    Wang W; Li Y; Rivera Rivera X; Zhao L; Mei D; Hu W; Jiang B
    BMC Cancer; 2021 Sep; 21(1):1011. PubMed ID: 34503477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
    Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
    Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 51. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy.
    Wang L; Liu P; Chen X; Geng Q; Lu Y
    Med Oncol; 2012 Sep; 29(3):2153-8. PubMed ID: 21877195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
    Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.
    Lanic H; Mareschal S; Mechken F; Picquenot JM; Cornic M; Maingonnat C; Bertrand P; Clatot F; Bohers E; Stamatoullas A; Leprêtre S; Rainville V; Ruminy P; Bastard C; Tilly H; Becker S; Vera P; Jardin F
    Leuk Lymphoma; 2012 Jan; 53(1):34-42. PubMed ID: 21806349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
    Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Mechanism of MiR-224 Affecting DLBCL Cell Proliferation and Invasion by Targeted Inhibition of PIK3CD].
    Xie Y; Tan L; Li YT; Zeng Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1578-1584. PubMed ID: 33067957
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
    Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
    Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.
    Ichikawa S; Fukuhara N; Katsushima H; Takahashi T; Yamamoto J; Yokoyama H; Sasaki O; Fukuhara O; Nomura J; Ishizawa K; Ichinohasama R; Muto A; Igarashi K; Harigae H
    Cancer Sci; 2014 Apr; 105(4):437-44. PubMed ID: 24450488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.